metformin has been researched along with Tuberous Sclerosis in 6 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Tuberous Sclerosis: Autosomal dominant neurocutaneous syndrome classically characterized by MENTAL RETARDATION; EPILEPSY; and skin lesions (e.g., adenoma sebaceum and hypomelanotic macules). There is, however, considerable heterogeneity in the neurologic manifestations. It is also associated with cortical tuber and HAMARTOMAS formation throughout the body, especially the heart, kidneys, and eyes. Mutations in two loci TSC1 and TSC2 that encode hamartin and tuberin, respectively, are associated with the disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Preclinical and clinical evidence involving metformin's role in epilepsy and special conditions like tuberous sclerosis have been reviewed in this paper." | 9.22 | A review on role of metformin as a potential drug for epilepsy treatment and modulation of epileptogenesis. ( Sarangi, SC; Singh, R; Singh, S; Tripathi, M, 2022) |
| "Both bortezomib and metformin have been proposed as potential therapeutics in TSC." | 5.38 | Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC). ( Auricchio, N; Kwiatkowski, DJ; Malinowska, I; Manning, BD; Shaw, R, 2012) |
| "Preclinical and clinical evidence involving metformin's role in epilepsy and special conditions like tuberous sclerosis have been reviewed in this paper." | 5.22 | A review on role of metformin as a potential drug for epilepsy treatment and modulation of epileptogenesis. ( Sarangi, SC; Singh, R; Singh, S; Tripathi, M, 2022) |
| "Metformin treatment appeared to attenuate mTORC1 signalling in Tsc1(+/-) kidney tissues but not in renal tumours." | 1.39 | Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin. ( Gallacher, J; Kalogerou, M; Sampson, JR; Shen, MH; Yang, J, 2013) |
| "Both bortezomib and metformin have been proposed as potential therapeutics in TSC." | 1.38 | Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC). ( Auricchio, N; Kwiatkowski, DJ; Malinowska, I; Manning, BD; Shaw, R, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, R | 1 |
| Sarangi, SC | 1 |
| Singh, S | 1 |
| Tripathi, M | 1 |
| Jurca, CM | 1 |
| Kozma, K | 1 |
| Petchesi, CD | 1 |
| Zaha, DC | 1 |
| Magyar, I | 1 |
| Munteanu, M | 1 |
| Faur, L | 1 |
| Jurca, A | 1 |
| Bembea, D | 1 |
| Severin, E | 1 |
| Jurca, AD | 1 |
| Howell, JJ | 1 |
| Hellberg, K | 1 |
| Turner, M | 1 |
| Talbott, G | 1 |
| Kolar, MJ | 1 |
| Ross, DS | 1 |
| Hoxhaj, G | 1 |
| Saghatelian, A | 1 |
| Shaw, RJ | 1 |
| Manning, BD | 2 |
| Xie, Z | 1 |
| Lau, K | 1 |
| Eby, B | 1 |
| Lozano, P | 1 |
| He, C | 1 |
| Pennington, B | 1 |
| Li, H | 1 |
| Rathi, S | 1 |
| Dong, Y | 1 |
| Tian, R | 1 |
| Kem, D | 1 |
| Zou, MH | 1 |
| Auricchio, N | 1 |
| Malinowska, I | 1 |
| Shaw, R | 1 |
| Kwiatkowski, DJ | 1 |
| Yang, J | 1 |
| Kalogerou, M | 1 |
| Gallacher, J | 1 |
| Sampson, JR | 1 |
| Shen, MH | 1 |
2 reviews available for metformin and Tuberous Sclerosis
| Article | Year |
|---|---|
A review on role of metformin as a potential drug for epilepsy treatment and modulation of epileptogenesis.
Topics: AMP-Activated Protein Kinases; Anticonvulsants; Epilepsy; Humans; Metformin; TOR Serine-Threonine Ki | 2022 |
Tuberous Sclerosis, Type II Diabetes Mellitus and the PI3K/AKT/mTOR Signaling Pathways-Case Report and Literature Review.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Epilepsy; Female; Humans; Infant; Metformin; Phosphati | 2023 |
4 other studies available for metformin and Tuberous Sclerosis
| Article | Year |
|---|---|
Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex.
Topics: AMP-Activated Protein Kinases; Animals; Dose-Response Relationship, Drug; Hepatocytes; Humans; Liver | 2017 |
Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin- | 2011 |
Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC).
Topics: Animals; Body Weight; Boronic Acids; Bortezomib; Disease Models, Animal; Humans; Immunoblotting; Imm | 2012 |
Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin.
Topics: Animals; Azacitidine; Blotting, Western; Catecholamine Plasma Membrane Transport Proteins; Decitabin | 2013 |